Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity.
Diphosphonates are known to affect calcium metabolism. It was therefore felt of interest to investigate the effects of SR 41319, a new Diphosphonate, comparatively to Etidronate disodium (EHDP) on Passive Cutaneous Anaphylaxis (PCA) and on Phospholipase A2 (PLA2) activity which are both mediated by calcium-dependent mechanisms. Results showed that: (1) intravenously, SR 41319 induced a dose-dependent inhibition of PCA more pronounced than the EHDP one; (2) in PLA2 assay, marked inhibition was obtained with SR 41319 whereas EHDP was slightly active. Decrease in Ca entry into mast cells and anti-PLA2 activity of SR 41319 might partly explain the SR 41319 inhibition of PCA.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology*; D012968:Etidronic Acid / Q000494:pharmacology*; D008297:Male; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects*; D010740:Phospholipases / Q000378:metabolism*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D051381:Rats
D004164:Diphosphonates; C045541:SR 41319; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D012968:Etidronic Acid; D002118:Calcium